INNOVENT BIO (01801): Davixin (ipilimumab N01 injection) has been approved by the National Medical Products Administration for use in combination with sintilimab in neoadjuvant therapy for colorectal cancer.
Innovent Biologics (01801) announced that Tyvyt (sintilimab injection, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody, research and development code: IBI310) has been approved by the National Medical Products Administration (NMPA) of China for commercialization. It can be used in combination with camrelizumab for neoadjuvant therapy in patients with stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer who are eligible for surgical resection.
INNOVENT BIO (01801) announced that Davixin (ipilimumab N01 injection, a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody (mAb) developed under the codename IBI310) has been approved by the National Medical Products Administration (NMPA) in China for marketing. It is used in combination with sincilimab for neoadjuvant therapy in patients with stage IIB-III microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer who are eligible for surgery. Davixin (ipilimumab N01 injection) is the first domestically approved anti-CTLA-4 mAb in China and the first globally approved anti-CTLA-4 mAb for neoadjuvant therapy in colorectal cancer. The short-term neoadjuvant therapy in combination with sincilimab significantly improves the rate of pathological complete response, benefiting patients with MSI-H/dMMR colorectal cancer.
Related Articles
HK Stock Market Move | China Tourism Group Duty Free Corporation (01880) is up nearly 7%. Its wholly-owned subsidiary was awarded the bid for Section 01 of the Beijing Capital International Airport Duty Free Project.
HK Stock Market Move | UBTECH ROBOTICS (09880) opens more than 7%, planning to acquire Zhejiang Fenglong Electric for 1.665 billion RMB. The humanoid Siasun Robot & Automation annual order total is nearly 1.4 billion RMB.
GF Securities: Initiates coverage on LAOPU GOLD (06181) with a "buy" rating. Fair value is 775.64 Hong Kong dollars.
HK Stock Market Move | China Tourism Group Duty Free Corporation (01880) is up nearly 7%. Its wholly-owned subsidiary was awarded the bid for Section 01 of the Beijing Capital International Airport Duty Free Project.
HK Stock Market Move | UBTECH ROBOTICS (09880) opens more than 7%, planning to acquire Zhejiang Fenglong Electric for 1.665 billion RMB. The humanoid Siasun Robot & Automation annual order total is nearly 1.4 billion RMB.
GF Securities: Initiates coverage on LAOPU GOLD (06181) with a "buy" rating. Fair value is 775.64 Hong Kong dollars.
RECOMMEND
Not Just “Power Shortages,” Delays Will Become The Key Theme For U.S. Data Centers In 2026
26/12/2025
Hang Seng Index Rises 33% This Year, Best Five‑Year Performance; Multiple Institutions Forecast Breakthrough Above 30,000 Next Year
26/12/2025
Gold Rally Has Further To Run, JPMorgan Bullish: Prices Could Reach USD 5,055 By Year‑End 2026
26/12/2025
